cyc 202 has been researched along with amifampridine in 2 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (amifampridine) | Trials (amifampridine) | Recent Studies (post-2010) (amifampridine) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 400 | 31 | 86 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cho, S; Meriney, SD | 1 |
| Adler, M; Apland, JP; Borrell, A; Deshpande, SS; Murray, B | 1 |
2 other study(ies) available for cyc 202 and amifampridine
| Article | Year |
|---|---|
The effects of presynaptic calcium channel modulation by roscovitine on transmitter release at the adult frog neuromuscular junction.
Topics: 4-Aminopyridine; Amifampridine; Animals; Calcium Channels; Excitatory Postsynaptic Potentials; Kinetin; Neuromuscular Junction; Patch-Clamp Techniques; Potassium Channel Blockers; Presynaptic Terminals; Protein Kinase Inhibitors; Purines; Rana pipiens; Roscovitine; Synaptic Transmission; Xenopus laevis | 2006 |
Reversal of BoNT/A-mediated inhibition of muscle paralysis by 3,4-diaminopyridine and roscovitine in mouse phrenic nerve-hemidiaphragm preparations.
Topics: 4-Aminopyridine; Amifampridine; Animals; Botulinum Toxins, Type A; Diaphragm; Male; Mice; Paralysis; Phrenic Nerve; Purines; Roscovitine | 2012 |